Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Equity (2016 - 2025)

Historic Return on Equity for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 5.2%.

  • Coherus Oncology's Return on Equity rose 71800.0% to 5.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.2%, marking a year-over-year increase of 71800.0%. This contributed to the annual value of 0.18% for FY2024, which is 16100.0% down from last year.
  • Latest data reveals that Coherus Oncology reported Return on Equity of 5.2% as of Q3 2025, which was up 71800.0% from 17.85% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Return on Equity ranged from a high of 45.8% in Q2 2022 and a low of 17.85% during Q2 2025
  • Over the past 5 years, Coherus Oncology's median Return on Equity value was 0.37% (recorded in 2021), while the average stood at 1.46%.
  • As far as peak fluctuations go, Coherus Oncology's Return on Equity surged by 469600bps in 2022, and later crashed by -443700bps in 2023.
  • Quarter analysis of 5 years shows Coherus Oncology's Return on Equity stood at 2.51% in 2021, then skyrocketed by 199bps to 2.49% in 2022, then crashed by -42bps to 1.45% in 2023, then tumbled by -380bps to 4.07% in 2024, then skyrocketed by 228bps to 5.2% in 2025.
  • Its last three reported values are 5.2% in Q3 2025, 17.85% for Q2 2025, and 1.7% during Q1 2025.